SAB BIOTHERAPEUTICS, INC. Equity Securities, FV-NI, Realized Gain
SAB BIOTHERAPEUTICS, INC. (SABS) reported Equity Securities, FV-NI, Realized Gain of $8.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-09.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedGain · last filed 2025-05-09
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, realized gain for the quarter ending 2025-03-31 was $8.00K.
| Period end | Equity Securities, FV-NI, Realized Gain 3 month |
|---|---|
| 2025-03-31 | $8.00K 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |